Landscape of targeted therapies for lung squamous cell carcinoma

Frontiers in Oncology, Год журнала: 2024, Номер 14

Опубликована: Окт. 31, 2024

Lung cancer, a common type of malignant neoplasm, has seen significant advancements in the treatment lung adenocarcinoma (LUAD). However, management squamous cell carcinoma (LSCC) continues to pose challenges. Traditional methods for LSCC encompass surgical resection, chemotherapy, and radiotherapy. The introduction targeted therapy immunotherapy greatly benefited patients, but issues such as limited immune response rates adverse reactions persist. Therefore, gaining deeper comprehension underlying mechanisms holds immense importance. This review provides an in-depth overview classical signaling pathways therapeutic targets, including PI3K pathway, CDK4/6 FGFR1 pathway EGFR pathway. Additionally, we delve into alternative potential targets that could offer new avenues LSCC. Lastly, summarize latest combined with checkpoint blockade (ICB) discuss prospects challenges this field.

Язык: Английский

Kanglaite alleviates lung squamous cell carcinoma through ferroptosis

International Immunopharmacology, Год журнала: 2024, Номер 144, С. 113616 - 113616

Опубликована: Ноя. 22, 2024

Язык: Английский